AimedBio's antibody-drug conjugate (ADC) candidate, AMB304, has been
selected by the Korea Drug
Development Fund (KDDF) for preclinical development over the next
two years.
AMB304 targets an undisclosed glycoprotein expressed on cancer cells,
delivering a topoisomerase I inhibitor to combat tumor progression, metastasis,
drug resistance, and poor prognosis in various cancers. It is being developed
for solid tumors, including colorectal and non-small cell lung cancers.
Preclinical studies showed strong anti-tumor efficacy and a favorable safety
profile.
AimedBio plans to submit IND applications to the U.S. FDA and Korea’s Ministry
of Food and Drug Safety (MFDS) by 2026, aiming to start Phase 1 clinical
trials.
“AMB304 differentiates itself from currently marketed ADC drugs in terms of its
target and preclinical efficacy profile. This selection will help accelerate
its entry into clinical development.” said Dr. Wonsik Jung, Director of
Preclinical Development. AimedBio recently out-licensed its lead TOP1-based ADC
candidate, AMB302 (BHV-1530), to Biohaven, and entered a co-development and
licensing agreement with SK Plasma for AMB303 (ROR1 ADC).
“We expect AMB304 to drive the next phase of our pipeline and expand our
next-generation ADC platform,” an AimedBio representative added.
Founded in 2018 as a Samsung Medical Center spin-off, AimedBio builds on over
30 years of pioneering brain tumor research led by Dr. Do-Hyun Nam. The company
has raised $82 million to date, including $38 million in a recent pre-IPO
funding round, as it continues to advance its robust pipeline of targeted
cancer therapies.